期刊文献+

3-甲基-8-喹啉磺酰氯的合成 被引量:1

Synthesis of 3-Methyl-8-quinolinesulphonyl Chloride
下载PDF
导出
摘要 以硝基苯作为起始原料,经还原后,与2-甲基丙烯醛环合,再与氯磺酸反应制备得到阿加曲班的关键中间体3-甲基-8-喹啉磺酰氯,结构经1H NMR、ESI-MS等确证,并对合成工艺进行了优化。优化条件下,总收率达78.4%(以硝基苯计),纯度达98.6%(HPLC)。制备方法操作简单,反应条件比较温和,使用的起始物料和试剂廉价易得,可用于工业化生产。 3-Methyl-8-quinolinesulphonyl chloride,the key intermediate of Argatroban monohydrate was prepared from nitrobenzene via reduction,cyclisation with 2-methacroleim and sulfonyl chloride reaction.The structure of target compound was identified by'H NMR and ESI-MS The reaction conditions for the synthesis of 3-methyl-8-quinolinesulphonyl chloride were optimized.The total yield of this target compound was improved to 78.4%with a purity of 98.6%.The improved process is facile with relatively convenient operation procedures and suitable for industrial production.
作者 谢月红 周季颖 汪锦娟 XIE Yue-hong;ZHOU Ji-ying;WANG Jin-juan*(Department of Pharmacy,Nanjing First Hospital,Nanjing Medical University,Nanjing 210000,China)
出处 《精细化工中间体》 CAS 2023年第5期23-25,共3页 Fine Chemical Intermediates
关键词 阿加曲班 硝基苯 2-甲基丙烯醛 argatroban monohydrate nitrobenzene 2-methacrolein
  • 相关文献

参考文献5

二级参考文献66

  • 1袁莉娟,刘爱民,刘蕾.新型凝血酶抑制剂阿加曲班[J].中国新药杂志,2005,14(2):230-234. 被引量:34
  • 2GREINACHER A, WARKENTIN TE. The direct thrombin inhibitor hirudin [ J ]. Thromb Haemost, 2008,99 ( 5 ) : 819 - 829.
  • 3WARKENTIN TE, GREINACHER A, KOSTER A. Bivalirudln [ J]. Thromb Haemost,2008,99 (5) :830 - 839.
  • 4YEH RW, JANG IK. Argatroban: Update [ J]. Am Heart J, 2006,151(6):1131-1138.
  • 5KEISU M, ANDERSSON TB. Drug-induced liver injury in humans: the case oi ximelagatran [ J ]. Hartdb Exp Pharmacot, 2010,196:407 - 418.
  • 6BLECH S, EBNER T, LUDWIG-SCHWELLINGER E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [ J ]. Drug Metab Dispos, 2008,36 (2) :386 -399.
  • 7ERIKSSON BI, DAHL OE, ROSENCHER N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blin956d, noninferiority trial[ J]. Lancet, 2007,370(9591 ) :949.
  • 8ERIKSSON BI, DAHL OE, ROSENCHER N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial [ J ]. J Thromb Haemost, 2007,5 ( 11 ) : 2178 -2185.
  • 9GINSBERG JS, DAVIDSON BL, COMP PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery [ J ]. J Arthroplasty, 2009,24 ( 1 ) : 1 - 9.
  • 10CONNOLLY SJ, EZEKOWITZ MD, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[ J]. N Engl J Med, 2009,361 (12) :1139 - 1151.

共引文献53

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部